Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · IEX Real-Time Price · USD
1.350
+0.030 (2.27%)
Jul 22, 2024, 10:19 AM EDT - Market open
Aclaris Therapeutics Employees
As of December 31, 2023, Aclaris Therapeutics had 91 total employees, including 86 full-time and 5 part-time employees. The number of employees decreased by 14 or -13.33% compared to the previous year.
Employees
91
Change (1Y)
-14
Growth (1Y)
-13.33%
Revenue / Employee
$341,967
Profits / Employee
-$849,033
Market Cap
96.21M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
111, Inc. | 1,520 |
LakeShore Biopharma | 773 |
Xtant Medical Holdings | 215 |
Asensus Surgical | 209 |
Assembly Biosciences | 65 |
Sensus Healthcare | 35 |
Eupraxia Pharmaceuticals | 29 |
Checkpoint Therapeutics | 23 |
ACRS News
- 5 days ago - Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - GlobeNewsWire
- 26 days ago - Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte) - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - American Clinical Research Services Announces Strategic Acquisition of Elixia - Business Wire
- 2 months ago - Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer - PRNewsWire
- 5 months ago - Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 months ago - Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis - GlobeNewsWire